Shanghai's Zai Lab has officially announced its IPO by filing an initial prospectus with the US SEC. According to the prospectus, Zai will seek to stage an IPO on the NASDAQ exchange for as much as $115 million. Details of the offering are not included ...


ChinaBio® Weekly Update

Contents


Zai Lab Files for $115 Million IPO in the US

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Shanghai's Zai Lab has officially announced its IPO by filing an initial prospectus with the US SEC. According to the prospectus, Zai will seek to stage an IPO on the NASDAQ exchange for as much as $115 million. Details of the offering are not included in the preliminary filing, though the filing specifies some operating details: Zai spent $32.1 million in R&D during 2016 and another $20.9 million during the first six months of 2017. On June 30, 2017, the company had $92.6 million in cash on hand after raising $164.5 million in equity financings over its three-year history. More details....

Share this with colleagues:

     
 

Antengene of Shanghai Announces a $21 Million Series A Round

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Antengene, a one-year-old Shanghai startup, completed a $21 million series A round, led by Qiming Venture Partners. Antengene plans to in-license drugs, ranging from mid-stage development to mature brands, for China and other East Asian markets. Earlier this year, Antengene acquired China/East Asia rights to a Celgene cancer candidate. Also participating in the A round were China VCs TF Capital and HG Capital, along with Tigermed Investment. Tigermed will conduct the China clinical trials of Antengene's lead drug. More details....

Stock Symbol: (NSDQ: CELG)

Share this with colleagues:

     
 

Lilly Asia Ventures Closes Fourth Fund with $450 Million

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Lilly Asia Ventures has closed its fourth China/Asia life science-focused fund at $450 million, a hard cap. This is over three times the $100 million of its previous fund, which closed in 2015. The new fund, known as LAV Biosciences Fund IV, took only two months to reach its cap, and was "significantly oversubscribed." Lilly, a company that is active in diabetes and cancer treatment, got its start in Asia/China venture capital with a $10 million investment in the BioVeda China fund in 2007, the first international VC fund dedicated to making life science investments in China. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:

     
 

Shanghai Ankon Raises $100 Million to Market Pill-like Endoscopy Device

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Shanghai Ankon Technologies raised $100 million in venture capital to market NaviCam, a swallow-able device about the size of a pill, for imaging the gastric track to diagnose stomach cancer and other gastric problems. The 15-minute minimally-invasive procedure provides doctors with an inside look of a patient's gastric track. Ankon wants to expand into new markets and develop similar systems for early diagnosis of other diseases. The round included investors SBCVC, Dazhong Investment, Youshi Capital and Tongsheng Capital. More details....

Share this with colleagues:

     
 

Shenzhen Royal Asset to Pay $33 Million for Fibrosis Candidates from Prometic

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Shenzhen Royal Asset Management (SRAM) will pay $33 million for China rights to three candidates aimed at fibrosis from Montreal's Prometic Life Sciences. SRAM will also own a 25% share in Prometic ChinaCo, a new JV that will manufacture the API for China use of the three molecules. SRAM will pay a royalty on China revenues to the JV and be responsible for China development of the in-licensed drugs, focusing initially on pulmonary and liver fibrosis. Prometic will use the $33 million for ex-China clinical trials of the three candidates. More details....

Stock Symbols: (TSX: PLI; OTCQX: PFSCF)

Share this with colleagues:

     
 

More Recent Articles

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.


 Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

Greg B. Scott
Executive Editor
ChinaBio® Today


ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC


Click here to safely unsubscribe from "ChinaBio® Today."
Click here to view mailing archives, here to change your preferences, or here to subscribePrivacy